Known targets — ChEMBL curated mechanism
ABL1BCRBLKEPHA2FGRFRKFYNHCKKITLCKLYNPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Dasatinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 10/20 | 1.00 |
| ▸ | SRC known ✓ | P12931 | 5/20 | 1.00 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 1.00 |
| ▸ | FYN known ✓ | P06241 | 2/20 | 1.00 |
| ▸ | YES1 known ✓ | P07947 | 2/20 | 1.00 |
| ▸ | LYN known ✓ | P07948 | 2/20 | 1.00 |
| ▸ | HCK known ✓ | P08631 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 2/20 | 1.00 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 1.00 |
| ▸ | FRK known ✓ | P42685 | 2/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | FGR known ✓ | P09769 | 1/20 | 1.00 |
| ▸ | BLK known ✓ | P51451 | 1/20 | 1.00 |
| ▸ | SRMS known ✓ | Q9H3Y6 | 1/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 8/20 | 1.00 |
| ▸ | SIK3 | Q9Y2K2 | 8/20 | 1.00 |
| ▸ | SIK1 | P57059 | 6/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasatinib Anhydrous SCHEMBL16618598 | 1.00 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL16618224 | 1.00 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL29482416 | 1.00 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL290515 | 1.00 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL16913911 | 0.99 | ABL1 (0.98) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL29381185 | 0.99 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL8226 | 0.99 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL28350326 | 0.99 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL1705152 | 0.98 | ABL1 (0.98) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL20857008 | 0.98 | ABL1 (0.98) | ABL1SIK2SIK3SIK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325310-A1 | PEDIATRIC FORMULATION OF TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2024-10-03 | — | — | US | claimed |
| EP-4125913-A1 | PEDIATRIC FORMULATION OF TYROSINE KINASE INHIBITORS | IGIA Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| EP-3349782-B1 | PHARMACEUTICAL ASSOCIATION COMPRISING A GROWTH FACTOR RECEPTOR AGONIST CONJUGATED TO A BIOACTIVE CARRIER FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | HISTIDE AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| EP-3784232-B1 | IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250388633-A1 | PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | HISTIDE AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20250352530-A1 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | MANNKIND CORP (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250288515-A1 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2025-09-18 | — | — | US | disclosed |
| EP-4611752-A1 | COMBINATION OF A TYROSINE KINASE INHIBITOR AND A PRO-INFLAMMATORY AGENT FOR TREATING CANCER | MDX Management LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3349777-B1 | PHARMACEUTICAL ASSOCIATION COMPRISING A GROWTH FACTOR RECEPTOR AGONIST CONJUGATED TO A BIOACTIVE CARRIERFOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | HISTIDE AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| US-20250114331-A1 | CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY | UNIV JOHNS HOPKINS (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4524235-A2 | PHARMACEUTICAL ASSOCIATION FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | Histide AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| US-20230058726-A1 | CHEMOPREVENTION USING CONTROLLED- RELEASE FORMULATIONS OF ANTI-INTERLEUKIN 6 AGENTS, SYNTHETIC VITAMIN A ANALOGUES OR METABOLITES, AND ESTRADIOL METABOLITES | OHIO STATE INNOVATION FOUNDATION | 2023-02-23 | — | — | US | disclosed |
| EP-4125913-A1 | PEDIATRIC FORMULATION OF TYROSINE KINASE INHIBITORS | IGIA Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023010141-A1 | CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-11484591-B2 | Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites | OHIO STATE INNOVATION FOUNDATION (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220273759-A1 | PHARMACEUTICAL ASSOCIATION FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | HISTIDE AG (CH) | 2022-09-01 | — | — | US | disclosed |
| EP-3998076-A1 | PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | Histide AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| US-11311548-B2 | Cancer therapy | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2022-04-26 | — | — | US | disclosed |
| CN-108938618-B | Compound for delaying human mesenchymal stem cell aging and application thereof | 中国科学院动物研究所 | 2022-04-22 | — | — | CN | disclosed |
| EP-3949975-A1 | PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | Histide AG (CH) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352530-A1 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | KIT, MAP3K15, PRKCZ | ABL1 677/4885SRC 1562/4885LCK 553/4885 |
| US-20220273759-A1 | PHARMACEUTICAL ASSOCIATION FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | CCNK, CCNA1, CCNA2 | ABL1 1245/4885SRC 658/4885LCK 1845/4885 |
| US-11311548-B2 | Cancer therapy | DHODH, MCL1, DOHH | ABL1 17/4885SRC 1009/4885LCK 2118/4885 |
| US-20250288515-A1 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | KIT, PRKCZ, MAP3K15 | ABL1 682/4885SRC 1776/4885LCK 687/4885 |
| US-20250388633-A1 | PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | SELPLG, ROR1, VCAM1 | ABL1 351/4885SRC 352/4885LCK 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.